Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 1,735 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 174
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
EUKARYOTIC HOST CELL FOR EXPRESSION VITAMIN K DEPENDENT PROTEIN, EXPRESSION VECTOR IN EUKARYOTIC CELLS, METHOD FOR MAKING GAMMA-CARBOXYLATED VITAMIN K DEPENDENT PROTEIN AND METHOD FOR MAKING PHARMACEUTICAL COMPOSITION FOR COAGULATION INDUCTION OR STIMULATION OF COAGULATION INCREASE OR DECREASE
RU10.11.2009
2006110147/13ФЕНГЕ Кристель (SE)
C12N 15/63
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
FIELD: medicine. SUBSTANCE: vitamin K dependent protein is made by separating a cultivated eukaryotic cell that contains an expressing vector that contains a nucleic acid molecule coding vitamin K dependent protein and associated sequences regulating expression. The associated sequences contain the first promoter and the nucleic acid molecule coding gamma-glutamylcarboxylase, and the second promoter. The first promoter represents a pre-early promoter of human cytomegalovirus (hCMV), and the second promoter is a pre-early promoter SV40. Herewith the expressing relation of vitamin K dependent protein and gamma-glutamylcarboxylase is 10:1 to 250:1. EFFECT: invention allows for making gamma-carboxylated vitamin K dependent protein in production quantities. 29 cl, 5 dwg, 6 tbl, 7 ex

Process for the production of anhydrosugar alcohols
CN29.04.2009
200780013774.6Archer-daniels-midland CompanySanborn Alexandra J.
C07D 493/06
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
06
Peri-condensed systems
A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.

TNFスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用
JP16.04.2009
2008540193サンタリス ファーマ アー/エスサザニ、 ペーター エル.
A61K 31/7088
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides

TNF受容体(TNFR1およびTNFR2)ならびにTNFRスーパーファミリーのその他の受容体の発現を、これらの受容体をコードする前駆体mRNAのスプライシングを調整する化合物を使用して制御するための、方法および組成物が開示される。より具体的には、これらの化合物により上記受容体の膜貫通ドメインが除去され、TNF−α活性または関連リガンドの活性を低減するアンタゴニストとして作用する可溶性の受容体が生じる。TNF−α活性を低減することにより、TNF−α活性に関連した炎症性の疾病または状態を治療または改善する方法が提供される。同様に、他のリガンドに関連した疾病も類似の方法で治療することができる。特に、本発明の化合物は、インビボにおいて安定で、RNAに配列特異的にハイブリダイズし、かつその標的と共にRNaseHによる分解を受けない小さな分子である、スプライス−スプライス切替オリゴマー(SSO)である。


CLEANSING COSMETIC COMPOSITION
JP30.07.2009
2008009846KOBAYASHI PHARMACEUT CO LTDITO MARE
A61K 8/86
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8
Cosmetics or similar toilet preparations
18
characterised by the composition
72
containing organic macromolecular compounds
84
obtained by reactions other than those involving only carbon-to-carbon unsaturated bonds
86
Polyethers
PROBLEM TO BE SOLVED: To provide a lamella crystal-type cleansing cosmetic composition excellent in the cleansing power for and the rinsability of messy makeup, and good in stability of withstanding its own long-term storage.

SOLUTION: The cosmetic composition, having a lamella liquid crystalline structure, comprises a component A as polyglyceryl mono- or dioleate, a component B as polyglyceryl mono- or diisostearate, water, and an oily component.

COPYRIGHT: (C)2009,JPO&INPIT


SKIN CARE PREPARATION FOR EXTERNAL USE
JP04.06.2009
2007295837SHISEIDO CO LTDMORI YUICHIRO
A61Q 19/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
Q
SPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
19
Preparations for care of the skin
PROBLEM TO BE SOLVED: To provide a humectant having an extremely excellent moisture retaining effect and fresh and youthful sense of use (sense of moisture retaining effect) and a skin care preparation for external use.

SOLUTION: The humectant comprises one or more selected from a lower alkyl pentitol ether represented by formula (I) [wherein A is a pentitol residue after the removal of m hydrogen atoms; R is a 1-4C alkyl group (including a hydroxyalkyl group); and m is an average substitution degree for R and a number of 1-5] and a lower alkyl hexitol ether represented by formula (II) [wherein B is a hexitol residue after removal of n hydrogen atoms; R is a 1-4C alkyl group (including a hydroxyalkyl group); and n is an average substitution degree for R and a number of 1-6]. The skin care preparation for external use comprises the humectant.

COPYRIGHT: (C)2009,JPO&INPIT


USE OF TRAP PROTEIN PER SE AS ACTIVE INGREDIENT FOR MANUFACTURING A MEDICAMENT FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTION
EP07.01.2009
07720819HAINAN GT UNIPUL PHARMACEUTICAL CO LTDYANG GUANG
A61K 38/16
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
The present invention discloses the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament comprising TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins of the present invention is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.

APPLES WITH HIGH POLYPHENOLIC CONTENT
KR21.05.2009
1020097004936CORESSENCE LIMITEDWOOD RICHARD
A23L 1/30
A HUMAN NECESSITIES
23
FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
L
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
1
Foods or foodstuffs; Their preparation or treatment
29
Modifying nutritive qualities of foods; Dietetic products
30
containing additives
The invention relates to apples comprising high concentrations of polyphenols, to processes for obtaining said apples and to uses of apples as a method of treatment or prophylaxis of cardiovascular disease, colon cancer and digestive health. ©KIPO&WIPO 2009

Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection
US10.12.2009
12226491Yang Guang
A61K 38/16
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.


METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND MARKERS IDENTIFIED BY SET ASSOCIATION
US15.10.2009
12487608Translational Genomics Research InstituteSTEPHAN Dietrich A.
A01K 67/027
A HUMAN NECESSITIES
01
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
K
ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67
Rearing or breeding animals, not otherwise provided for; New breeds of animals
027
New breeds of vertebrates

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.


Methods of diagnosing alzheimer's disease and markers identified by set association
US01.10.2009
12148728Stephan Dietrich A.Stephan Dietrich A.
C12Q 1/68
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.


Results 1-10 of 1,735 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 174